Australian court rejects Boehringer opposition bid against MSD unit’s anti-parasitic drug patent
24-05-2022
Merck & Co to buy $1bn stake in Seattle Genetics
16-09-2020
Partial win for Mylan as Fed Circuit cancels Boehringer patents
17-03-2020
nitpicker / Shutterstock.com
The Federal Court of Australia has rejected Boehringer Ingelheim’s animal health unit's attempt to stop the registration of a patent owned by Intervet International on various grounds.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Boehringer Ingelheim, Intervet International, Merck & Co, patent registration, animal health, Federal Court of Australia, parasites
